ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2016
MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- LncRNA CYP4A22-AS1 promotes the progression of lung adenocarcinoma through the miR-205-5p/EREG and miR-34c-5p/BCL-2 axes.Cancer cell international · 2023Article
- Article
- Mesenchymal stem cell-derived exosomes as new tools for delivery of miRNAs in the treatment of cancer.Frontiers in bioengineering and biotechnology · 2022Review
- Knockdown of lncRNA TapSAKI alleviates LPS-induced injury in HK-2 cells through the miR-205/IRF3 pathway.Open medicine (Warsaw, Poland) · 2021Article
- miR-205 in Breast Cancer: State of the Art.International journal of molecular sciences · 2020Review
- Review
- Article
- Genetic ablation of bone marrow beta-adrenergic receptors in mice modulates miRNA-transcriptome networks of neuroinflammation in the paraventricular nucleus.Physiological genomics · 2020Article
- miR-205/RunX2 axis negatively regulates CD44American journal of cancer research · 2020Article
- Automated Five-Color Multiplex Co-detection of MicroRNA and Protein Expression in Fixed Tissue Specimens.Methods in molecular biology (Clifton, N.J.) · 2020Article
- Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility.Breast cancer (Dove Medical Press) · 2020Review
- miR-205-3p promotes proliferation and reduces apoptosis of breast cancer MCF-7 cells and is associated with poor prognosis of breast cancer patients.Journal of clinical laboratory analysis · 2019Article
- Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity.Cancers · 2019Review
- Exosomal microRNA-205 is involved in proliferation, migration, invasion, and apoptosis of ovarian cancer cells via regulating VEGFA.Cancer cell international · 2019Article
- Expression signatures and roles of microRNAs in inflammatory breast cancer.Cancer cell international · 2019Review
- Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.Nature communications · 2018Article
- Transcriptome Signatures of Canine Mammary Gland Tumors and Its Comparison to Human Breast Cancers.Cancers · 2018Article
- MicroRNAs in regulation of triple-negative breast cancer progression.Journal of cancer research and clinical oncology · 2018Review
- Inflammatory breast cancer biology: the tumour microenvironment is key.Nature reviews. Cancer · 2018Review
- Proliferation-associated miRNAs-494, -205, -21 and -126 detected by in situ hybridization: expression and prognostic potential in breast carcinoma patients.Journal of cancer research and clinical oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 1 country.
Funding
Abstract
Inflammatory breast cancer is the most aggressive form of breast cancer. Identifying new biomarkers to be used as therapeutic targets is in urgent need. Messenger RNA expression profiling studies have indicated that inflammatory breast cancer is a transcriptionally heterogeneous disease, and specific molecular targets for inflammatory breast cancer have not been well established. We performed microRNA expression profiling in inflammatory breast cancer in comparison with locally advanced noninflammatory breast cancer in this study. Although many microRNAs were differentially expressed between normal breast tissue and tumor tissue, most of them did not show differential expression between inflammatory and noninflammatory tumor samples. However, by microarray analysis, quantitative reverse transcription PCR, and in situ hybridization, we showed that microRNA-205 expression was decreased not only in tumor compared with normal breast tissue, but also in inflammatory breast cancer compared with noninflammatory breast cancer. Lower expression of microRNA-205 correlated with worse distant metastasis-free survival and overall survival in our cohort. A small-scale immunohistochemistry analysis showed coexistence of decreased microRNA-205 expression and decreased E-cadherin expression in some ductal tumors. MicroRNA-205 may serve as a therapeutic target in advanced breast cancer including inflammatory breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.